Buffered Lidocaine Syringes at Brooke Army Medical Center, JBSA Ft. Sam Houston, TX

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

W40M MRC0 WEST

Contract Value

Not provided

Codes & Classification
Solicitation Number

W81K00-26-Q-A001

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6515

Additional Details
Set Aside

SBA

Place of Performance

JBSA Ft Sam Houston, Texas, UNITED STATES

SourceSAM
Documents2
The Department of the Army, under the auspices of the DEPT OF DEFENSE, has issued a Combined Synopsis/Solicitation for the procurement of Buffered Lidocaine Syringes to be delivered to Brooke Army Medical Center, located at Joint Base San Antonio (JBSA) Ft. Sam Houston, Texas. The solicitation, identified by procurement number W81K00-26-Q-A001, is managed by the contracting office W40M MRC0 WEST. This procurement seeks to secure pharmaceutical preparation manufacturing services, specifically the supply of buffered lidocaine syringes, classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6515. The intended outcome is to ensure the timely and compliant delivery of these medical products to support the operational needs of Brooke Army Medical Center. Offerors are required to demonstrate strict compliance with federal regulations, including those outlined by the FDA, as well as applicable state regulations governing the production and distribution of pharmaceutical products. Proof of regulatory compliance is a critical evaluation factor. Additionally, offerors must provide detailed pricing for each contract line item (CLIN), either within the Continuation of Supplies or Services and Prices/Costs section or as a separate document. The solicitation is set aside for Small Business Administration (SBA) eligible entities, emphasizing the government’s commitment to supporting small business participation. Potential contractors must be registered in the System for Award Management (SAM) to be eligible for award, and confirmation of completed and accurate SAM provisions must accompany the offer. Submission requirements include completion of the SF1449 form (specifically Blocks 17, including CAGE code and Unique Entity ID Number, and Blocks 30 A-C), a statement affirming that the quote will remain firm for at least 90 days from the due date, and completion of all solicitation provisions. Quotes must be submitted electronically via email to both Patrick Thielemann ([email protected]) and Christopher Gregory ([email protected]) no later than 11:00 AM Central Time on June 24, 2026. Questions regarding the solicitation must be submitted in writing by 11:00 AM Central Time on June 15, 2026, to the same contacts. Offerors are responsible for ensuring that their entire submission is received by the government server by the stated deadline; files larger than 20MB should be sent in separate emails. The place of performance for this contract is JBSA Ft. Sam Houston, Texas, USA. The opportunity remains active and is accessible via the SAM.gov portal (Opportunity ID: 73b2f5c7f73f48c3a4c40ea8daca601f), where additional attachments related to the solicitation are available. This procurement represents a stable, ongoing requirement for compliant pharmaceutical manufacturing and supply, with a focus on regulatory adherence, competitive pricing, and timely delivery. Contractors with proven capabilities in pharmaceutical preparation and distribution, particularly those meeting SBA small business criteria, are encouraged to review the solicitation in detail and consider submitting a response.